LONDON (Alliance News) - Sensyne Health PLC and the life sciences company Bayer AG on Tuesday said they will work together on the development of a UK linked patient data capability.
Under the terms, Bayer will work with the consortium members as they develop proposals to scale Sensyne Health's current network of strategic research agreements with NHS Trusts. Consortium members include Microsoft Corp, Ernst & Young, JPMorgan, and Peel Hunt.
The artificial intelligence technology company said the purpose of this network is to accelerate the discovery and development of new medicines and improve patient care through the analysis of large databases of anonymised patient data.
"Access to anonymised national linked patient data heralds a new era in the discovery and development of medicines," said Bayer Director Kemal Malik.
"Through the application of artificial intelligence to large sets of patient information it becomes possible to identify people that are most likely to be at risk of diseases in the future. Importantly, this will allow steps to prevent their progress along that path," added Malik.
Sensyne Health shares were trading 0.3% lower on Tuesday at 177.52 pence each in London.
